Metastatic Urothelial Carcinoma Pipeline Analysis (2023) Covering Clinical Trials, Emerging Therapies, FDA, EMA, and PMDA Approvals, Competitive Landscape | PharmaMar, Ectin, Exelixis, Merck, Seagen

Posted on
by

Delveinsight Business Research LLP
As per DelveInsight’s assessment, globally, about 40+ key pharma and biotech companies are working on 40+ pipeline drugs in the Metastatic Urothelial Carcinoma therapeutics landscape based on different Routes of Administration (ROA), Mechanism of Action (MOA), and molecule types. Several of the therapies are in the advanced stages of clinical development and are expected to launch in the coming years.

“Metastatic Urothelial Carcinoma Pipeline Insight, 2023” report by DelveInsight outlines a comprehensive assessment of the present clinical/non-clinical development activities and growth prospects across the Metastatic Urothelial Carcinoma Market. 

The Metastatic Urothelial Carcinoma Pipeline report embraces in-depth commercial, regulatory, and Metastatic Urothelial Carcinoma clinical trial assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the emerging Metastatic Urothelial Carcinoma drugs, including the mechanism of action, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers, acquisition, funding, designations, and other product-related details.

Metastatic Urothelial Carcinoma Pipeline Analysis

The report provides insights into: 

  • The report provides detailed insights into the emerging therapies for Metastatic Urothelial Carcinoma treatment and the aggregate therapies developed by major pharma companies.

  • It accesses the different Metastatic Urothelial Carcinoma therapies segmented into early-stage, mid-stage, and late-stage clinical development.

  • It outlines the major Metastatic Urothelial Carcinoma companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

  • The report evaluates the Metastatic Urothelial Carcinoma drugs that are under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 

  • It navigates the major collaborations (company-company collaborations and company-academia collaborations), licensing agreements, financing details, data presentation by the pharma giants, and regulatory approval in the Metastatic Urothelial Carcinoma therapeutic market.

Metastatic Urothelial Carcinoma Therapeutics Landscape

Urothelial Carcinoma, also known as transitional cell carcinoma (TCC), is characterized by cancer beginning in the urothelial cells lining the bladder, it is one of the most common forms of bladder cancer (BC). Treatment for metastatic form of Urothelial Carcinoma (UC) can be employed in different classes of chemotherapy, immunotherapy, radiation therapy, target-specific therapy, and surgical treatment. Metastatic Urothelial Carcinoma has shown poor survival when treated with chemotherapy; however, due to the advancements in the treatment of new immunotherapies, more alternatives are available.

Chemotherapy majorly forms the first line of treatment, mainly comprising platinum-based products. Cisplatin-based chemotherapy is a chief product in the list of chemotherapeutics. The commonly used cisplatin regimens include MVAC (methotrexate, vinblastine, doxorubicin, cisplatin) or GC (gemcitabine and cisplatin). Cisplatin is followed by Carboplatin for therapeutic regimens, such as M-CAVI (methotrexate, carboplatin, and vinblastine). A few nonplatinum regimens include gemcitabine with a taxane (either paclitaxel or docetaxel) rather than platinum. Single-agent chemotherapy also holds importance in the treatment routine, including Gemcitabine, Vinflunine, and Ifosfamide.

The major class of treatment also comprises Immunotherapy, which helps the patient’s own immune system to recognize and destroy cancer cells. Developments in this domain have led to the development of immune checkpoint inhibitors (ICIs) targeting the programmed death (PD-1/PDL-1) pathway. Immunotherapy is used in platinum ineligible or refractory cases. The market holds Atezolizumab (Tecentriq), Pembrolizumab (Keytruda), Nivolumab (Opdivo), Durvalumab (Imfinzi), and Avelumab (Bavencio) as approved products targeting PD-1/PDL-1 pathway.

There are approx. 40+ key companies developing therapies for Metastatic Urothelial Carcinoma. Currently, PharmaMar is leading the therapeutics market with its Metastatic Urothelial Carcinoma drug candidates in the most advanced stage of clinical development.

Metastatic Urothelial Carcinoma Companies Actively Working in the Therapeutic Market Include:

  • PharmaMar

  • Ectin Research AG

  • Exelixis

  • Eli Lilly and Company

  • Merck Sharp & Dohme LLC

  • Astellas Pharma Inc

  • Seagen Inc.

  • Shanghai Miracogen Inc.

  • Advaxis, Inc.

And Many Others

Emerging and Marketed Metastatic Urothelial Carcinoma Drugs Covered in the Report Include:

  • MFA 370: Ectin Research AG

  • XL 092: Exelixis

  • Lurbinectedin: PharmaMar

  • Ramucirumab: Eli Lilly

  • Infigratinib: QED Therapeutics

  • Rogaratinib: Bayer

  • Pemigatinib: Incyte Corporation

  • Sacituzumab govitecan: Immunomedics

  • NKTR-214: Nektar Therapeutics/Bristol-Myers Squibb

  • RX-3117: Rexahn Pharmaceuticals

And Many More

Request the Sample PDF to Get a Better Understanding of the Emerging Drugs and Metastatic Urothelial Carcinoma Companies Working in the Market @ 

https://www.delveinsight.com/sample-request/metastatic-urothelial-carcinoma-pipeline-insight

Analysis of Emerging Metastatic Urothelial Carcinoma Therapies by Phases

The report covers the emerging products under different phases of clinical development like –

  • Late-stage products (Phase III)

  • Mid-stage products (Phase II)

  • Early-stage products (Phase I) 

  • Pre-clinical and Discovery stage candidates

  • Discontinued and inactive candidates

Route of Administration

Metastatic Urothelial Carcinoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

  • Intra-articular

  • Intraocular

  • Intrathecal

  • Intravenous

  • Ophthalmic

  • Oral

  • Parenteral

  • Subcutaneous

  • Topical

  • Transdermal

Molecule Type

Products have been categorized under various Molecule types such as

  • Oligonucleotide

  • Peptide

  • Small molecule

Learn How the Metastatic Urothelial Carcinoma Treatment Outlook will Evolve with the Ongoing Clinical and commercial Activities in the Therapeutic Market @

https://www.delveinsight.com/sample-request/metastatic-urothelial-carcinoma-pipeline-insight

Table of Content (TOC)

1. Report Introduction

2. Executive Summary

3. Metastatic Urothelial Carcinoma Treatment Patterns

4. Metastatic Urothelial Carcinoma – DelveInsight’s Analytical Perspective

5. Therapeutic Assessment

6. Metastatic Urothelial Carcinoma Late Stage Products (Phase-III)

7. Metastatic Urothelial Carcinoma Mid-Stage Products (Phase-II)

8. Metastatic Urothelial Carcinoma Early Stage Products (Phase-I)

9. Pre-clinical Products and Discovery Stage Products

10. Inactive Products

11. Dormant Products

12. Metastatic Urothelial Carcinoma Discontinued Products

13. Metastatic Urothelial Carcinoma Product Profiles

14. Major Metastatic Urothelial Carcinoma Companies in the Market

15. Key Products in the Metastatic Urothelial Carcinoma Therapeutics Segment

16. Dormant and Discontinued Products

17. Metastatic Urothelial Carcinoma Unmet Needs

18. Metastatic Urothelial Carcinoma Future Perspectives

19. Metastatic Urothelial Carcinoma Analyst Review  

20. Appendix

21. Report Methodology

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

Download Sample PDF to Explore the Key Offerings of the Report @

https://www.delveinsight.com/sample-request/metastatic-urothelial-carcinoma-pipeline-insight

 

 

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.

Other Trending Healthcare Reports By DelveInsight

Nicotine Addiction Market

“Nicotine Addiction Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of the historical and forecasted epidemiology as well as the Nicotine Addiction market size, share, trends, and growth analysis in the seven major markets (i.e. the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan. Moreover, it also covers the current treatment practices, emerging drugs, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the Nicotine Addiction market.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/medical-devices